Application of nanoprobiotics and nanoprebiotics in intestinal damage caused by indomethacin: an experimental animal model

• Grant number: 22/11913-6
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: February 01, 2023
• End date: January 31, 2024
• Field of knowledge: Health Sciences - Pharmacy
• Principal Investigator: Lizziane Kretli Winkelströter Eller
• Grantee: Kimberlly de Oliveira Silva
• Host Institution: Faculdade de Ciências da Saúde (FCSA). Universidade do Oeste Paulista (UNOESTE). Presidente Prudente , SP, Brazil

Abstract

Functional gastrointestinal disorders are recognized by morphological and/or physiological abnormalities, and are associated with an imbalance in some of the protective mechanisms of the gastrointestinal tract. Some factors can lead to the appearance of these disorders, such as the use of some medications, diet and lifestyle. Indomethacin, a non-steroidal anti-inflammatory drug, is widely prescribed, however, it can result in tissue damage, inflammation, cytotoxicity, cell apoptosis and cell cycle alteration, mainly in the gastrointestinal tract (GIT). Nutraceuticals, prebiotics and probiotics have been applied in a vast field of health, as bioactive components that exert anti-inflammatory, antioxidant, antiproliferative, immunomodulatory effects, among others. Recently, an unprecedented growth in the field of nanomedicine research has been observed. Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanoparticles (NPs) have been increasingly applied in the diagnosis and treatment of diseases and their use in medicine has been encouraged due to the improvement of human health. In this context, this project aims to evaluate the impact of nanoparticles of bioactive food compounds on indomethacin-induced intestinal damage in in vivo experiments. Nanoparticles will be developed by the gelation method from chitosan with probiotic (Pediococcus acidilactici CE51) and probiotic + prebiotic (oligofructose). The nanoparticles will be characterized as to size, morphology and efficiency of encapsulation and drug release. For in vivo tests, 54 male mice strain Mus musculus (C57BL/6), aged 6-8 weeks, divided into six groups (controls, induction with indomethacin and nanoparticles of bioactive food components) will be used. The treatment time will be 14 days. After euthanasia will be performed histopathological analysis, serious biochemical measurements, evaluation of genotoxicity and metagenomic analysis of the intestinal microbiota. The results will be statistically evaluated considering a confidence level of 0.05. Results are expected to indicate and guide a future application of food bioactives in the form of nanoparticles to alleviate gastrointestinal disorders.